RESPIRATORY SYNCYTIAL VIRUS INFECTION
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS INFECTION explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS INFECTION trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Pfizer tracks RSV shot safety in over 1,000 seniors
⭐️ VACCINE ⭐️ OngoingThis study is monitoring the safety of the Abrysvo RSV vaccine in adults aged 60 and older in Japan. It will follow about 1,100 people for 28 days after they receive the vaccine to check for any side effects. The goal is to confirm the vaccine's safety in real-world use after its…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 27, 2026 12:39 UTC
-
First-of-its-Kind triple virus vaccine tested in seniors
⭐️ VACCINE ⭐️ OngoingThis early-stage study is testing a new vaccine designed to protect against three common respiratory viruses: RSV, human metapneumovirus, and parainfluenza type 3. Researchers are giving different dose combinations to 390 adults aged 60 and older to check if the vaccine is safe a…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE1 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 23, 2026 15:19 UTC
-
Scientists test which RSV shield works best for babies
Prevention OngoingThis study aims to find out which of two approved methods provides better and longer-lasting protection for babies against severe RSV, a common and dangerous respiratory virus. Researchers will compare giving a vaccine to pregnant mothers, giving a protective antibody shot to new…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTION
Phase: PHASE4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Mar 23, 2026 15:16 UTC